Sample records for adenolymphoma

  1. [A 20-year retrospective histoclinical analysis of parotid gland tumors in the ENT Department AM in Katowice]. (United States)

    Gierek, Tatiana; Majzel, Krystyna; Jura-Szołtys, Edyta; Slaska-Kaspera, Aleksandra; Witkowska, Małgorzata; Klimczak-Gołab, Lucyna


    Salivary gland neoplasms represent the diverse group of tumours encountered by the head and neck surgeons. The study is analysis of 531 patients with parotid gland tumours in patients treated in ENT Department during 1986-2006. We analysed surgical treatment and intraoperative tumour stage. The results of histological diagnosis were presented. The frequency of incidence of benign neoplasm was 80%. The most frequent tumour was pleomorphic adenoma--75% and adenolymphoma--16%. Malignant tumours constituted 20% of all gland tumours. Mucoepidermoid (27%) and adenoid cyst (22%) carcinomas were the most common malignant tumour. Tumour stages T3-T4 was in 90%.

  2. F-18 FDG PET in the initial evaluation of high risk melanoma

    Energy Technology Data Exchange (ETDEWEB)

    Wagner, T.; Zerdoud, S.; Faurie, C.; Chevreau, C.; Courbon, F. [Institut Claudius Regaud, 31 - Toulouse (France)


    Introduction. - Localized melanoma is a potentially aggressive tumor. Its prognosis depends mainly on pathologic factors, namely: thickness (Breslow index), presence of ulceration and microscopic nodal metastasis. FDG PET is the modality of choice for evaluation of advanced melanoma and has proven its superiority in terms of sensitivity, specificity and accuracy compared to conventional imaging. Early stages of melanoma do not seem to benefit from PET FDG. However the value of PET FDG in staging localized high risk melanoma is yet to be determined. Patients and methods. - We have evaluated 87 patients with high risk melanoma with PET FDG. 32 patients presented with a Breslow index superior or equal to 4 mm, 21 with a Breslow index inferior to 4 mm and ulceration and 34 with a positive sentinel lymphadenectomy. PET FDG was realized after at least 6 h of fasting on a hybrid PET-CT G.E. Discovery S.T. scan for 65 of them. The rest of the patients were evaluated on a Siemens Ecat H.R. + scan. Scans were interpreted by an experimented nuclear medicine physician and were classified as positive or negative. All equivocal scans or cases for which there was discordance between the scan result and follow up were reviewed by 2 experimented nuclear medicine physicians and a consensus was reached. Results. - FDG PET was positive in seven patients, four scans were true positive and identified regional metastatic disease. No distant metastatic visceral disease was found. The three false positive scans consisted of a cyst adeno-lymphoma in one case, mediastinal and axillary uptake in the other two cases and no sign of evolution more than six months after the scan. Four patients with a negative scan showed metastatic disease in the six months following the PET scan. FDG PET had an impact on therapeutic management on two patients (2%). When evaluating FDG PET for regional disease with sentinel node biopsy as a reference, we found values of sensitivity, specificity, predictive